MTHFD2 expression was remarkably elevated in UCB, suggesting that MTHFD2 could be a promising biomarker for BLCA as well as novel target for anti-cancer immunotherapy since its close association with immune infiltration. The gene discussed is MTHFD2; the disease is bladder transitional cell carcinoma.